Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aiolos Bio Inc.
Headquarters: San Francisco, CA, United States of America
Website: N/A
Year Founded: 2023
Status: Acquired
BioCentury | Mar 18, 2025
Management Tracks
Zenas names Lisa von Moltke head of R&D and CMO
Plus: CBC’s Lan Kang becomes CEO of Azkarra, and updates from Ionctura, Sunbird and Surf Bio
BioCentury | Mar 15, 2025
Editor's Commentary
The NewCo model spurs debate, but it’s about more than money — a Perspective
Expanding the dealmaker’s toolkit to bring Asian innovation to the West
BioCentury | Mar 3, 2025
Deals
The dealmaking at the heart of the NewCo boom
Formed with Hummingbird assets, $187M, Callio brings trend to Singapore
BioCentury | Feb 7, 2025
Deals
Under Bain’s ownership, Mitsubishi Tanabe to seek deals, growth in Japan
Japanese pharma’s parent chooses $3.4B buyout to create PE-backed standalone company
BioCentury | Feb 1, 2025
Finance
Investors with deep China roots lead NewCo surge, inspiring Western VCs
Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global
BioCentury | Jan 29, 2025
Deals
The NewCo boom signals China’s galloping speed of innovation
Companies founded in the West with Asian assets tell a story of China speed
BioCentury | Sep 24, 2024
Management Tracks
BMS alum Catherine Owen Adams to lead Acadia
Plus: René van der Merwe named CMO of Bambusa, and updates from ModeX and ChromaDex
BioCentury | May 22, 2024
Deals
Biogen’s ‘pick and choose’ strategy in immunology leads to $1B HI-Bio takeout
Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others
BioCentury | Feb 3, 2024
Finance
Series A companies: the class of 2023
An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors
BioCentury | Jan 13, 2024
Finance
JPM wrap: a BioCentury podcast
Takeouts, neuroscience innovation and investor sentiment to kick off 2024
Items per page:
1 - 10 of 14